How Vaginal Infections Impact Women’s Everyday Life <br/>—Women’s Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis

Reoccurring symptoms and persistent problems that continue post treatment can be characteristic of the vaginal infections Bacterial Vaginosis (BV) and recurrent vulvovaginal candidiasis (RVVC). The purpose of this study was to describe women’s life experiences in managing the symptoms of bacterial vaginosis and Candida. Sixteen women were recruited and participated in an interview study when they contacted a Swedish gynecology clinic with vaginal complaints that ranged from and included abnormal discharge, irritation itching along with serious malodor. An interpretive phenomenological approach was used with an individual interview to get a more intimate understanding of the women experiencing these problems. The finding of this study shows that managing the recurrent symptoms of the infections remains to be a challenge for women as it has a clearly negative impact on the quality of their lives. Four themes developed: frustration and mood disorders, intimacy changes in the relationship, exposure, hope and relief. The women had high hopes of eliminating the symptoms within the six-month study period. The treatment program, with its well-developed guidelines and continuity of care within the context of the study greatly improved the quality of life of these women. Women had feelings of frustration and anxiety when nothing could cure their problem while they had also a great hope to get rid of the symptoms with a long striking treatment. Well-developed guidelines and continuity of care can help these women to have an improved quality of life.

Treatment of Vulvovaginal Candidiasis with A Strategy Based on Phototherapy (M.A.C.® Scar Acceleration Method)

Candidiasis, also known as candidiasis vulvovaginitis, is an infection caused by different types of Candida fungi, the most frequent being Candida albicans. The present study reports an effective strategy, which opens new avenues for the treatment of this public health problem. The MAC® Methodology, conventional laser light-emitting (LLLT)/LED) methods are based on the biphasic response demonstrated many times in LLLT research and as with other forms of drugs, a “drug” (irradiation parameters) and a “dose” (irradiation times) and the “Arndt-Schulz Law” is often cited as a suitable model to describe the dose-dependent effects of LLLT. This method uses photopharmaceuticals, cell markers and the use of correct parameters for each case to induce the acceleration of tissue repair. The present study shows a case of a 32-year-old patient diagnosed with recurrent candidiasis 4 years ago. Eighteen sessions were performed (every other day) using a photoactivated component (Methylene blue 1% + Clotrimazole 1%) and LED phototherapy (red, blue and violet) with emission times of 60 - 260 seconds for each applicator, according to the dose recommendations of the scar acceleration method (MAC®). At the sixth treatment session there was a noticeable decrease in the itching sensation reported by the patient. In session 11 she reported feeling a great improvement, indicating that she no longer felt itching in any area after 18 sessions. The present case demonstrates new methodologies to treat common problems in the population that have a positive impact on the quality of life. This methodology has a promising future because it is non-invasive and requires a great biological transformation for inflammatory, fungal and viral control.

Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine

Therapy of chronic recurrent vulvovaginal can- didiasis (VVC) caused by Candida glabrata is still rare in comparison to C. albicans infection, but therapy remains more difficult. Combination therapy with topical antifungals may improve therapy outcome, but still standard agents as fluconazole or itraconazole often fail. Posaconazole is a new systemic triazole with a wide antifungal spectrum including rare Candida species. Up to now, no clinical trials with posa- conazole in chronic recurrent VVC have been undertaken. Here, first results of the application of a new therapy regimen consisting of oral posaconazole in combination with topical ciclopiroxolamine are presented. 15 patients with chronic recurrent VVC caused by C. glabrata have been treated. 14 of these patients experienced successful therapy, clinical and mycological cure 30 days after begin of therapy has been observed. Long-term results are promising, as in 4 patients clinical and mycologic cure persists for more than 1 year up to now.

Prevalence of Non-<i>Albicans Candida</i>Infections in Women with Recurrent Vulvovaginal Symptomatology

Background: Candida vulvovaginitis is one of the most frequently diagnosed conditions in women’s care practices. Historically, 90% of cultured yeast species were C. albicans. However, due to a variety of interventions, the proportion of non-albicans Candida (NAC) infections appears to be increasing. We sought to estimate the current prevalence of Candida vulvovaginitis and the species-specific distribution of such infections in recurrent cases. Methods: Women with recurrent vulvovaginal symptomatology referred to an Obstetrics and Gynecology practice were tested by genital fungus culture, Candida-specific polymerase chain reaction (PCR), or both between July 2010 and February 2013. Results: A total of 103 women were tested. Mean age was 45.6 years. Including only their most recent positive test result, 29.1% (30/103) of women tested positive for Candida by any of the above testing measures. Of those, 50% (15/30) tested positive for C. albicans and 50% (15/30) tested positive for a NAC species. Across all visits, 60% (18/30) tested positive for C. albicans, 56.7% (17/30) tested positive for NAC, and 16.7% (5/30) tested positive for both a C. albicans and a NAC species. Among all isolated NAC species, 28.6% (6/21) were determined to be C. glabrata, 23.8% (5/21) C. krusei, 23.8% (5/21) C. parapsilosis, and 23.8% (5/21) other Candida species. Conclusion: Approximately 30% of women with recurrent vulvovaginal symptomatology have detectable Candida strains and it appears that NAC species may cause half of all these infections. This is imperative because NAC infections are usually more difficult to diagnose and are resistant to most treatments.

Polyhexamethylene Biguanide in Vaginal Solution Is Effective in the Treatment of Vulvovaginal Candidiasis: A Pilot Study

Vaginitis is one of the most recurrent conditions that afflict women and require medical care. Vulvovaginal candidiasis (VVC) is frequently related to vaginal carriage of Candida albicans, an opportunistic polymorphic fungus, which colonizes the human skin, the mucosa and the reproductive tract. Actually, standard treatments to counteract vaginitis include several topical and oral treatments. The aim of this study was to evaluate the efficacy of a new biguanide compound, polyhexamethylene biguanide (PHMB) in avaginal solution, in women affected by vaginal candidiasis. For this reason, 40 women showing the symptoms previously ascribed to vaginal candidiasis were recruited and treated with a single PHMB dose of vaginal solution. After a single dose of treatment, 80% of them had a complete resolution of the fungal infection;furthermore, all of them reported clinical benefits, statistically significant reduction in both clinical signs and symptoms of candidiasis and a score’s reduction of 50%.

Alpha Defensins Genes and Vulvovaginal Candidiasis:A Study of Cases

Objective: To evaluate the alpha-defensin (α-DF) genes polymorphism in women with vulvovaginal candidiasis and recurrence. Methods: This observational study included clinical vaginal secretion samples collected over four years from 88 women, ranging in age from 18 to 65 years, from medical centers of Sao Paulo and Mogi das Cruzes, Brazil. Thirty-six of these women were asymptomatic (control group) and 52 presented clinical condition compatible with vulvovaginitis (38 primary or episodic as non-recurrent forms, and 14 recurrent vulvovaginal candidiasis). A portion of each sample was plated on Sabouraud dextrose agar with chloramphenicol and grown on CHROMagar Candida for presumptive characterization. The identification of the species was obtained by sequencing of the ITS1 region of rDNA. α-DF genes were amplified for subsequent evaluation of polymorphisms by endonuclease restriction assay. Results: From 88 samples were isolated 60 Candida albicans and 28 non-albicans Candida spp. Resistant C. albicans strains and non-albicans Candida spp. were more prevalent in recurrence. In all groups, the number of resistant non-albicans Candida spp. was most high than susceptible strains. α-DF1, α-DF3 and α-DF1/α-DF3 genotypes were found in 32 (36.4%), 17 (19.3%), 6 (6.8%) vaginal samples, respectively. About 33 samples were not amplified. Recurrence and severe disease were more observed in homozygous population. Conclusions: Non-albicans Candida spp. and homozygotic α-DF genotipes (α-DF1 and α-DF3) were more related with severe clinical signs and recurrence. Further studies about vulvovaginal candidiasis and α-DF genes are necessary to access the more comprehensive role of defensins in clinical manifestations.

Features of vaginal bacteria community in women with recurrent vulvovaginal candidiasis

Objective To investigate the features of vaginal bacteria community in women with recurrent vulvovaginal candidiasis （R VVC） and its etiological risk in vaginal health. Methods Totally 237 reproductive-aged women with RVVC in an acute episode were studied. Whereas 230 healthy reproductive-aged women were enrolled as the control. The vaginal pH was evaluated, while vaginal secretions were sampled for Gram＇s staining and oilmicroscopy. By Nugent score system, the composition of vaginal communities was determined, and other micro-ecological features were approached. To describe other features of vaginal microbiota, the community＇s bacteria density, species diversity and predominant species were evaluated at 1 000 X magnification. Results The vaginal pH （4.53 ~ 0.30） and Nugent score （4.31 ___＋ O. 73） in RVVC group were significantly increased compared with vaginal pH （4.11 __＋ 0.30） and Nugent score （1.32 _＋ 1.29） in control group （P〈O.05, respectively）. The density of Lactoba- cillus in RVVC group was significantly lower than that in control group （P〈O.05）, while the densities of Gardnerella vaginalis, Gram-positive cocci and other species were significantly higher respectively than those in control group （P〈O. 05）. Species diversity of women with RVVC significantly exceeded that of control group （P〈O.05）. More than half of vaginal communities in R VVC group lost Lactobacillus-dominating and were predominated by other bacteria such as Gardnerella vaginalis and Gram-positive cocci. The prevalence of Gardnerella vaginalis-dominating and Gram-positive cocci-domi- nating communities in RVVC group （37.55% and 19.83%） were significantly higher than those in control group （1.30% and 1.73%） （P〈0.05）. Conclusion The significant changes in vaginal bacterial community were observed in RVVC women. Such variations in community might relate to vaginal biological barrier compromising and increase the risk to the recurrence of VVC. It is still controversial whether probiotics can prevent recurrences of VVC, and more randomized, doubleblind, placebo-controlled trials with a larger sample size should be carried out, so as to clarify its effects for the prophylaxis of RVVC.

Growing importance of urogenital candidiasis in individuals with diabetes:A narrative review

Both diabetes and fungal infections contribute significantly to the global disease burden,with increasing trends seen in most developed and developing countries during recent decades.This is reflected in urogenital infections caused by Candida species that are becoming ever more pervasive in diabetic patients,particularly those that present with unsatisfactory glycemic control.In addition,a relatively new group of anti-hyperglycemic drugs,known as sodium glucose cotransporter 2 inhibitors,has been linked with an increased risk for colonization of the urogenital region with Candida spp.,which can subsequently lead to an infectious process.In this review paper,we have highlighted notable virulence factors of Candida species(with an emphasis on Candida albicans)and shown how the interplay of many pathophysiological factors can give rise to vulvovaginal candidiasis,potentially complicated with recurrences and dire pregnancy outcomes.We have also addressed an increased risk of candiduria and urinary tract infections caused by species of Candida in females and males with diabetes,further highlighting possible complications such as emphysematous cystitis as well as the risk for the development of balanitis and balanoposthitis in(primarily uncircumcised)males.With a steadily increasing global burden of diabetes,urogenital mycotic infections will undoubtedly become more prevalent in the future;hence,there is a need for an evidence-based approach from both clinical and public health perspectives.

Clinical Experience in the Treatment of Vulvovaginal Candida Disease with Integrated Traditional Chinese and Western Medicine

Summarizing two cases of vaginal candidiasis,cured by integrated traditional Chinese and western medicine in clinical work,it is found that the combination of traditional Chinese and western medicine has a significant effect on the treatment of this disease.The curative effect is outstanding,and the recurrence rate is significantly reduced,which can be used as a reference for gynecological medical workers.

Expression of Candida Albicans Secreted Aspartyl Proteinase in Acute Vaginal Candidiasis

In order to analyze the in vivo expression of Candida albicans secreted aspartyl pro- teinases (SAP) in human vaginal infection, the vaginal secretion from 29 human subjects was col- lected by vaginal swab, and the expression of SAP1–SAP6 was detected by reverse-transcriptase po- lymerase chain reaction using specific primer sets. It was found that Sap2 and Sap5 were the most common genes expressed during infection; Sap3 and Sap4 were detected in all subjects and all 6 SAP genes were simultaneously expressed in some patients with vaginal candidiasis. It was suggested that the SAP family is expressed by Candida albicans during infection in human and that Candida albi- cans infection is associated with the differential expression of individual SAP genes which may be involved in the pathogenesis of vaginal candidiasis.

Patient Preferences in the Treatment of Vaginal Candidiasis

Vulvovaginal candidiasis (VVC) is one of the most frequent problems facing women and their healthcare professionals (HCP). It is difficult for providers to understand the prevalence of VVC because effective over the counter treatments (OTC), are available. It is expected that there are a great many more episodes of VVC in our patient population, as the frequency of self-treatment, success and satisfaction for those that use OTC products prior to seeing a women’s health care provider is unknown. In this study;healthcare providers were given OTC miconazole/tioconazole units for free distribution to patients for whom they diagnosed VVC by exam in their offices. Surveys for both HCP and patients were also distributed to determine the initial or recurrent nature of their symptoms and their satisfaction with their treatments. 1265 OBGYNs and 1821 NP/CNM/PAs reported on over 19,000 patients receiving a single complete treatment. Among HCPs, treatment efficacy was the primary reason for recommending miconazole/tioconazole. However, rapid onset of symptom relief, safety vs. fluconazole, patient preference for the less messy ovule, avoidance with drugs metabolized by the liver, and resistance to, or failure on, fluconazole were additional reasons noted for topical preference. Overall, patient satisfaction (n = 317) was high at 95%, with 97% of patients reporting that they would use miconazole again. Importantly, 100% of first time sufferers (n = 95) would use miconazole again. The few patients dissatisfied with miconazole (2%), reported no symptom relief, burning after use, an “allergic reaction”, pain from the applicator or a messy discharge. Most patients using the external symptom relief products were satisfied with the external cream (93%) and wipes (96%). Almost all patients reported their yeast infection was cured (91%) and that they experienced quick symptom relief (94%), despite the prevalence of recurrent vs first time VVA sufferers that presented to offices in this trial. Most patients were cured and satisfied with their treatment, therefore supporting the use of topical miconazole/tioconazole as first line therapy for vulvovaginal candidiasis patients presenting to a healthcare office.

Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis

OBJECTIVE:To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis(VVC)using a systematic review and Meta-analysis of randomized controlled trials.METHODS:A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019.Randomized controlled trials in the treatment for VVC were included;only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with miconazole alone were included.Relative risk(RR)and 95%confidence intervals(CI)were used in the Meta-analysis.RESULTS:Seven studies involving 768 patients suffering from VVC were identified;468 of the patients were pregnant women(60.9%).Combination group(Redcore lotion plus miconazole)was more effective in redu CIng symptomatic episodes of VVC than miconazole alone,with respect to cure rate(RR,1.31;95%CI,1.09-1.57;P=0.01),fungal culture negative rate(RR,1.21;95%CI,1.04-1.41;P=0.01),and effective rate(RR,1.18;95%CI,1.05-1.35;P=0.01).Subgroup analyses for pregnant women also showed that the combination group had superior outcomes with respect to VVC cure rate(RR,1.48;95%CI,1.16-1.88,P<0.01),fungal culture negative rate(RR,1.26;95%CI;1.09-1.47;P<0.01),and effective rate(RR,1.25;95%CI,1.10-1.42;P<0.01).Additionally,the observed risk of adverse events was lower in the combination medication group(RR,0.30;95%CI,0.14-0.65;P<0.01).CONCLUSIONS:Though overall quality of individual studies was low,Redcore lotion plus miconazole can significantly improve clinical effectiveness and safety compared with miconazole alone.

An Epidemiologic Analysis of Vulvovaginal Candidiasis and Antifungal Susceptibilities

Inflammation of the vagina and vulva caused by Candida is called vulvovaginal candidiasis(VVC).Risk factors for VVC include pregnancy,diabetes mellitus,frequent oral sexual intercourse,and the use of tight synthetic underwear and systemic antibiotics.Candida albicans,which belongs to the normal flora of the vagina,is the most common cause of VVC.However,an increase in VVC episodes caused by non-albicans Candida species,including Candida glabrata,Candida tropicalis,Candida krusei and Candida parapsilosis,has been reported.In this study,a total of 100 Candida isolates obtained from patients with vaginitis symptoms were evaluated.The susceptibility of the Candida strains to amphotericin B,itraconazole,fluconazole,ketoconazole,voriconazole and caspofungin was investigated using the reference broth microdilution method.Risk factors and demographic characteristics of the patients and the identified Candida species were also investigated.Among the 100 Candida strains isolated from vaginal samples,47(47%)were C.albicans,43(43%)C.glabrata,5(5%)C.kefyr,2(2%)C.krusei,2(2%)C.tropicalis and 1(1%)was Candida guilliermondii.The incidences of Candida susceptibility to caspofungin,fluconazole,itraconazole,voriconazole,ketoconazole and amphotericin B were 75%,35%,27%,80%,97%and 100%,respectively.Also,there was a significant difference in antifungal susceptibility among patients belonging to certain risk groups,such as patients previously using antibiotics and recurrent cases.Prevalence of non-albicans Candida species and antifungal resistance,especially against azoles,are both increasing,and certain risk factors should be monitored strictly.

Susceptibility to Fluconazole and Ketoconazole of Candida spp. Isolated from Primary and Episodic Vulvovaginites by E-Test (São Paulo, SP, Brazil)

Purpose: To evaluate the profile of in vitro susceptibility of yeasts isolated from cases of primary and espisodic vulvovaginitis to two antifungal agents. Methods: 40 Candida isolates from episodes of vulvovaginal candidiasis were identified by classic methodologies. The susceptibility testing of the in vitro fluconazole and ketoconazole activity against the isolates was accessed by E-test. Results: C. albicans was the most common species identified in 70% of the occurrences followed by C. glabrata (20%), C. tropicalis (7.5%), and C. guilliermondii (2.5%). In the susceptibility profile to antifungal agents, 12.5% and 16.7% of the isolates obtained from primary and episodic vulvovaginal candidiasis were resistant to fluconazole, respectively. To ketoconazole, we found that 6.25% and 12.5% of the isolates respectively from primary vulvovaginal candidiasis (PVVC) and episodic vulvovaginal candidiasis (EVVC) had high MIC values. Conclusions: E-test is a reliable method for the susceptibility testing of Candida spp. due to its simplicity, reproducibility, and lack of specialized equipment. Resistant strains and non-albicans species were verified more in cases of EVVC than in PVVC. Clinical and mycological cure of patients with episodic vulvovaginal candidiasis or complicated cases occurred after prolonged treatment and sometimes with multiple antifungals use.

Pathogenetic treatment of candidal vulvovaginitis

The paper presents the possibility of the combined use of antimycotic sertaconazole nitrate and probiotics Fermalac to optimize the treatment of vulvovaginal candidiasis during and outside of pregnancy.Application of Fermalac allows to control the effectiveness and duration of antimycotic therapy.Combine therapy provides elimination of the pathogen in 100% of non-pregnant and 40% of pregnant patients.

完带汤防治脾虚湿盛型外阴阴道假丝酵母菌病的临床疗效及对DNA损伤的影响

目的探讨完带汤治疗脾虚湿盛型外阴阴道假丝酵母菌病(Vulvovaginal candidiasis,VVC)的临床疗效及对DNA损伤的影响。方法将符合纳入标准的70例脾虚湿盛VVC患者随机分为完带汤组和氟康唑组各35例,治疗期间2组各脱落5例。氟康唑组采用150 mg氟康唑口服一次;完带汤组采用完带汤口服14 d。治疗后比较2组患者中医证候积分变化情况;评估2组患者临床治愈(Test of cure,TOC)率及临床缓解(Clinical improvement,CI)率;比色法检测阴道灌洗液中8-羟基脱氧鸟苷(8-hydroxydeoxyguanosine,8-OHDG)水平变化以评估DNA损伤情况;治疗后3月评估患者访视临床完全缓解(Follow up,FU)、真菌学转阴及复发率。结果治疗后,2组患者中医证候积分均呈现不同程度改善(P<0.05,P<0.01);完带汤组优于氟康唑组(P<0.05,P<0.01);完带汤组TOC、CI、真菌学转阴率与氟康唑组未见明显差异(P>0.05);但完带汤组FU及复发率均显著优于氟康唑组(P<0.05,P<0.01)。治疗后,氟康唑组阴道灌洗液中8-OHDG表达显著增加(P<0.001),完带汤组未见明显变化,显著低于氟康唑组(P<0.001)。结论完带汤总体临床疗效与氟康唑相当,但在改善中医证候、防止复发方面优于氟康唑,同时具有不加剧阴道细胞DNA损伤的优势。

雌激素和Candidalysin在外阴阴道念珠菌病中的研究进展

外阴阴道念珠菌病(VVC)主要由白念珠菌(CA)引起。增加外周血雌激素水平如怀孕、口服避孕药的使用和激素替代疗法等增加VVC易感性。雌激素可通过调控CA菌丝生长、宿主固有免疫细胞和阴道上皮细胞的免疫功能等多种方式影响VVC进展,但具体机制仍不清楚。Candidalysin(CL)是一种对黏膜感染至关重要的真菌肽毒素,在CA感染中起着重要作用。CL由ECE1基因编码,雌激素调控ECE1表达。本文就雌激素和CL与VVC之间相关性进行综述,为进一步明确雌激素和CL在VVC发病机制中的作用提供参考。

包头地区295例VVC分离株的菌种分布及药物敏感性分析

目的:探讨包头地区外阴阴道念珠菌病(vulvovaginal candidiasis,VVC)患者感染念珠菌菌种分布特点及对抗真菌药物的敏感性,为临床精准治疗提供参考。方法:收集2021年1月至12月295例VVC患者阴道分泌物进行分离培养,应用MALDI-TOFMS、PCR方法完成菌种鉴定,按照CLSI M27-S4标准采用微量肉汤稀释法进行9种药物体外药敏试验。结果:感染患者以31~35年龄段最多见(30.85%),其次是26~30年龄段(20.34%),21~40年龄段患者占82.04%,性生活、妊娠等易感因素在VVC中占比较大;共分离鉴定出非重复菌株295株,白念珠菌居首位占79.32%,光滑念珠菌次之占13.90%,尼瓦利亚、布加拉等少见念珠菌共7种各1株;白念珠菌对伊曲康唑的耐药率高于非白念珠菌(P<0.01),二者对氟康唑、伏立康唑和泊沙康唑耐药情况差异无统计学意义(P>0.05),非白念珠菌对卡泊芬净和5-氟胞嘧啶的耐药率高于白念珠菌(P<0.01);未发现制霉菌素耐药菌株,所有菌株对两性霉素B的敏感性均为100%,对特比奈芬的耐药率均很高。结论:包头地区VVC患者感染菌种多样,以白念珠菌多见,但不同菌种念珠菌对常用抗真菌药物敏感情况差异较大,应定期进行持续的耐药监测,以便指导妇科医生制订正确的诊疗方案,同时延缓耐药性的产生。

育龄期复发性外阴阴道假丝酵母菌病病人自我管理影响因素的质性研究

目的:探讨影响复发性外阴阴道假丝酵母菌病(RVVC)病人自我管理行为的相关因素,为RVVC病人预防控制措施的构建提供依据。方法:采用现象学研究方法,对10名医护人员及10例病人进行半结构深入访谈,运用Colaizzi 7步分析法进行内容分析。结果:提炼出行为态度(长时间治疗易致病人产生消极自我管理行为、认知偏差导致自我管理重要性认识缺乏)、主观规范(社会现状对疾病包容性不足、家庭成员对疾病控制支持有限)、知觉行为控制(疾病专业知识获取局限、自我管理实际操作能力欠缺、自我管理客观原因拘束)3种类别7个主题。结论:RVVC病人自我管理行为的维持受多重因素影响,护理人员应通过改变病人主观行为认知、降低外界给予的压力以及提供必要的客观条件支持3个方面促进病人行为改进,提高病人的自我管理能力。

西安地区女性患者阴道微生态分析及阴道炎分布特征研究

目的探究西安地区女性患者阴道微生态特点和阴道炎分布特征,以便为临床治疗提供可靠的参考依据。方法选取2018年1月~2023年8月于陕西省人民医院就诊的102124例女性作为研究对象,采集患者阴道分泌物标本,并对阴道微生态状况进行检测和分析。结果102124例女性患者中,99.87%存在阴道微生态失衡,主要疾病类型为念珠菌性阴道炎(vulvovaginal candidiasis,VVC),占16.03%;细菌性阴道炎(bacterial vaginosis,BV),占9.61%和滴虫性阴道炎(trichomonal vaginitis,TV),占1.34%。通过统计分析发现,VVC,BV和TV患者年龄以21~30岁为主,在夏秋季时VVC,BV患病率高于其他季节,而TV的患病率在夏季相对较高。另外,在101995例阴道微生态失衡的女性患者中,有27552例单纯性阴道炎患者(27.01%)和1443例混合性阴道炎患者(1.42%)。在混合性阴道炎患者中,BV+VVC组合占了绝大多数(79.00%),年龄段主要在21~40岁之间。在28995例阴道炎患者中,有4308例复发患者(14.86%),其中单纯性阴道炎复发率(11.44%,3152/27552)远远低于混合性阴道炎复发率(80.11%,1156/1443)。结论西安地区女性单纯性阴道炎类型主要为VVC,在夏秋季患病率较高,混合性阴道炎的类型主要为BV+VVC。与单纯性阴道炎相比,混合感染患者更易复发。